Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

BG Baumert, ME Hegi, Martin van den Bent, A von Deimling, T Gorlia, K Hoang-Xuan, AA Brandes, G Kantor, MJB Taphoorn, M Ben Hassel, C Hartmann, G Ryan, D Capper, J.M. Kros, S Kurscheid, W Wick, R Enting, M Reni, B Thiessen, F DhermainJacoline Bromberg, L Feuvret, JC Reijneveld, O Chinot, JMM Gijtenbeek, J P Rossiter, N Dif, C Balana, J Bravo-Marques, PM Clement, C Marosi, T Tzuk-Shina, R A Nordal, J Rees, D Lacombe, WP Mason, R Stupp

Research output: Contribution to journalArticleAcademicpeer-review

292 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1521-1532
Number of pages12
JournalLancet Oncology
Volume17
Issue number11
DOIs
Publication statusPublished - 2016

Cite this